Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | IL1B | P01584 | 4/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.35 |
| ▸ | RORC | P51449 | 6/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 3/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27379299 | 0.87 | HDAC4 (0.36) | NR3C2TP53POLBMEN1KMT2A | |
| SCHEMBL30755433 | 0.87 | HDAC4 (0.36) | NR3C2TP53POLBMEN1KMT2A | |
| SCHEMBL30755381 | 0.85 | P2RX7 (0.35) | HSD11B1NR3C2IL1BP2RX7RORC | |
| SCHEMBL27379422 | 0.85 | P2RX7 (0.35) | HSD11B1NR3C2IL1BP2RX7RORC | |
| SCHEMBL30755472 | 0.85 | IDH1 (0.35) | HSD11B1IL1BP2RX7TP53SCN10A | |
| SCHEMBL27378973 | 0.83 | MEN1 (0.38) | IL1BP2RX7MEN1KMT2AATM | |
| SCHEMBL27375857 | 0.81 | MEN1 (0.36) | IL1BP2RX7RORCTP53MEN1 | |
| SCHEMBL27375885 | 0.81 | CA12 (0.37) | HSD11B1IL1BP2RX7RORCMEN1 | |
| SCHEMBL30755212 | 0.81 | CA12 (0.37) | HSD11B1IL1BP2RX7RORCMEN1 | |
| SCHEMBL27379265 | 0.80 | MEN1 (0.33) | NR3C2POLBMEN1KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034123-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4562016-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024026483-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026483-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034123-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK1, CDK20 | HSD11B1 818/4885NR3C2 60/4885IL1B 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.